Artificial hearts and support systems gain prominence in Germany
This article was originally published in Clinica
A fall in the number of donor hearts available and a simultaneous rise in the number of patients with severe heart insufficiency has promoted new therapy concepts, in which artificial heart technology is playing an increasingly important role. This was the view expressed by experts last week at the scientific symposium of the medical device industry association's (BVMed's) project group on ventricular assist devices and artificial hearts (VAD/Kunstherz) at the annual meeting of the German Cardiology Association in Mannheim.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.